Imfinzi (durvalumab)

P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Dec 2027 --> Apr 2028

P3, N=1407, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Dec 2026

P3, N=430, Not yet recruiting, PrECOG, LLC.

P3, N=330, Active, not recruiting, Radiation Therapy Oncology Group | Trial completion date: Jan 2025 --> Nov 2028 | Trial primary completion date: Jan 2025 --> Nov 2028 | Completed --> Active, not recruiting

The tumor burden was small without metastasis. This case highlights that ICI hepatitis can progress with minimal aminotransferase elevation in advanced cirrhosis, warranting multidimensional monitoring beyond aspartate aminotransferase/alanine aminotransferase, including bilirubin, coagulation parameters, clinical decompensation, and quantitative imaging.

Sequential VCN-01 plus durvalumab was better tolerated than concomitant treatment. The recommended VCN-01 phase 2 dose (RP2D) was 1.0E13 vp, on the sequential schedule. Encouraging survival was observed in patients after progressing on anti-PD-(L)1 agents. Data supports VCN-01 replication associated with increased PD-1, PD-L1, and CD8 tumor expression. Sequential systemic delivery of VCN-01 and anti-PD-L1 therapy may represent an improved treatment for HNSCC.

Durvalumab plus T-DXd demonstrated clinically relevant efficacy for first-line treatment of metastatic HR-negative, HER2-low breast cancer, with no unexpected toxicities observed. ClinicalTrials.gov identifier: NCT03742102 .

P2, N=33, Not yet recruiting, University of Washington | Initiation date: Jun 2026 --> Sep 2026

P1/2, N=6, Terminated, University of Nebraska | Trial completion date: Mar 2026 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Sep 2025; Poor accrual

This dissociation between PFS and OS may reflect differences in disease biology, treatment sequencing, and post-progression management rather than intrinsic superiority of either regimen. These findings highlight the importance of individualized treatment selection and careful consideration of tumor characteristics and hepatic reserve when choosing first-line immunotherapy for uHCC.

The phase III PACIFIC trial established consolidation durvalumab as the standard of care, demonstrating significant improvements in progression-free survival (PFS) and overall survival (OS)...The phase III LAURA trial demonstrated a substantial PFS benefit with consolidation osimertinib in patients with EGFR-mutated stage III NSCLC after definitive CRT. Ongoing research is focused on optimizing treatment sequencing, including induction chemoimmunotherapy approaches, radiation dose intensification strategies such as stereotactic boosts, and integration of targeted therapies for actionable genomic alterations. In this review, we summarize the current evidence guiding the management of unresectable stage III NSCLC, highlight advances in radiation and systemic therapies, and discuss emerging strategies aimed at improving locoregional control and long-term survival.

P3, N=310, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting